- Hypoglycaemia is defined as blood glucose <3.0 mmol/L, but below 2.5 mmol/L is considered pathological requiring investigation.
- In hospitalised patients, any blood glucose ≤4.0 mmol/L should be treated if the patient is symptomatic.
- The glucose level that is considered hypoglycaemic in children is still debated, particularly in neonates. Older literature suggests levels above 1.7 mmol/L are acceptable in this age group. The World Health Organization (WHO) defines hypoglycaemia in children as levels below 2.5 mmol/L.
The diagnosis of hypoglycaemia rests on three criteria (Whipple's triad) of plasma hypoglycaemia, symptoms attributable to a low blood sugar level and resolution of symptoms with correction of the hypoglycaemia.
The annual prevalence of severe hypoglycaemia is around 30% in people with type 1 diabetes. It is higher in those with risk factors, eg strict glycaemic control, impaired awareness of hypoglycaemia and increasing duration of diabetes. It is also common during sleep - nocturnal hypoglycaemia.
Risk factors for hypoglycaemia
- Tight glycaemic control.
- Injection into lipohypertrophy sites.
- Insulin prescription error (notable in hospitalised patients).
- Long duration of diabetes.
- Renal dialysis.
- Drug interactions between hypoglycaemic agents, eg quinine, selective serotonin reuptake inhibitors (SSRIs).
- Impaired renal function.
- Lack of anti-insulin hormone function, eg Addison's disease, hypothyroidism.
Neurological manifestations include coma, convulsions, transient hemiparesis and stroke, while reduced consciousness and cognitive dysfunction may cause accidents and injuries. Cardiac events may be precipitated, eg arrhythmias, myocardial ischaemia and cardiac failure.
Management in adults
Essentially, a quick-acting carbohydrate needs to be given, followed by longer-acting carbohydrate.
- Glucose 10-20 g is given by mouth, either in liquid form or as granulated sugar (2 teaspoons) or sugar lumps.
- GlucoGel® - formerly known as Hypostop® Gel - may be used.
If hypoglycaemia causes unconsciousness, or the patient is unco-operative
- 75-80 ml 20% glucose or 150-160 ml of 10% glucose (the volume will be determined by the clinical scenario).
- 25 ml of 50% glucose concentration is viscous, making it more irritant and more difficult to administer, and rarely used now.
Once the patient regains consciousness, oral glucose should be administered, as above.
If the patient is at home, or intravenous (IV) access cannot be rapidly established
- Glucagon 1 mg should be given by intramuscular (IM), or subcutaneous (SC) injection.
- This dose is used in insulin-induced hypoglycaemia (by SC, IM, or IV injection), in adults and in children over 8 years (or bodyweight over 25 kg). NB: 1 unit of glucagon = 1 mg of glucagon.
Glucagon can have variable absorption, as it is given SC or IM. It has a relatively slow onset of action and relies on glycogen stores.Therefore, it may not be effective in cachectic patients, those with liver disease, and in young children. It is contra-indicated in insulinoma and phaeochromocytoma. It also causes more insulin to be released and creates the potential for secondary rebound hypoglycaemia.
Once the patient is more alert, longer-acting carbohydrate should be given, eg toast, a normal meal. For inpatients, an infusion of 10% glucose may need to be considered, eg 100 mL/hour. If the patient received glucagon then a larger portion of the longer-acting carbohydrate is needed. Also, they may need their regular insulin if it is due - although the dose may need to be reviewed.
Prolonged hypoglycaemic coma
This is usually caused by cerebral oedema, and follows profound hypoglycaemia lasting more than five hours:
- Use IV mannitol and dexamethasone with constant glucose monitoring and IV glucose to keep serum level at 5-10 mmol/L until either consciousness has been restored or permanent brain damage is diagnosed.
- With overdoses of insulin or sulphonylurea, up to 80 g/hour glucose as 25-50% solution through a central line may be required.
Treatment of hypoglycaemia in children
Prompt treatment of hypoglycaemia in children, from any cause, is essential to prevent subsequent neurological damage. Hyperinsulinism, fatty acid oxidation disorders and glycogen storage disease are less common causes of acute hypoglycaemia in children.
- Glucose 10-20 g is given by mouth either in liquid form, eg milk 200 mL, or as granulated sugar (2 teaspoons) or sugar lumps.
- If necessary, this may be repeated following 10-15 minutes.
- Further food is required to prevent recurrence of hypoglycaemia.
Hypoglycaemia which causes unconsciousness or fitting is an emergency
- In hypoglycaemia, if sugar cannot be given by mouth, glucagon can be given by injection. A child aged under 8 years or of bodyweight under 25 kg should be given 500 micrograms.
- Carbohydrates should be given as soon as possible to restore liver glycogen.
- Glucagon may be issued to parents or carers of insulin-treated children for emergency use in hypoglycaemic attacks.
- It is often advisable to prescribe on an 'if necessary' basis to hospitalised insulin-treated children, so that it may be given rapidly by the nurses during a hypoglycaemic emergency.
- If not effective in 10 minutes, IV glucose should be given.
Alternatively, 2-5 mL/kg of glucose IV infusion 10% (200-500 mg/kg of glucose) may be given IV into a large vein, through a large-gauge needle.
- This concentration is irritant, especially if extravasation occurs.
- Glucose IV infusion 50% is not recommended, as it is very viscous and hypertonic.
The patient should be monitored closely, particularly in the case of an overdose with a long-acting insulin because further administration of glucose may be required.
Octreotide appears to be a safe and effective treatment where glucose therapy is escalating in sulphonylurea overdose. Bolus doses of 1-2 mcg/kg can be given every 6-8 hours or an infusion of 30 ng/kg/min; however, the optimal dosing regime is debated and a toxicologist or endocrinologist should be consulted.
Glucagon is not effective in the treatment of hypoglycaemia due to fatty acid oxidation or glycogen storage disorders. Glucagon is not appropriate for chronic hypoglycaemia.
- Neonatal hypoglycaemia is treated with glucose IV infusion 10% given at a rate of 5 mL/kg/hour.
- An initial dose of 2.5 mL/kg over five minutes may be required if hypoglycaemia is severe enough to cause loss of consciousness, or fitting.
- Mild asymptomatic persistent hypoglycaemia may respond to a single dose of glucagon.
- The dose is 20 mcg per kg.
- Glucagon has also been used in the short-term management of endogenous hyperinsulinism.
Prevention of hypoglycaemia is a crucial part of the management of diabetes mellitus and all cases should be followed up and reviewed.
Further reading & references
- Diagnosis and management of type 1 diabetes in children, young people and adults; NICE Clinical Guideline (July 2004)
- Type 2 diabetes: the management of type 2 diabetes (update), NICE Clinical Guideline (May 2008)
- McAulay V, Deary IJ, Frier BM; Symptoms of hypoglycaemia in people with diabetes.; Diabet Med. 2001 Sep;18(9):690-705.
- Cox D, Gonder-Frederick L, McCall A, et al; The effects of glucose fluctuation on cognitive function and QOL: the functional costs of hypoglycaemia and hyperglycaemia among adults with type 1 or type 2 diabetes.; Int J Clin Pract Suppl. 2002 Jul;(129):20-6.
- Marks V in Oxford Textbook of Medicine, 4th Edition. Eds; Warrell DA et al. OUP 2003
- The Hospital Management of Hypoglycaemia in Adults with Diabetes Mellitus, NHS Diabetes (March 2010)
- Achoki R, Opiyo N, English M; Mini-review: Management of hypoglycaemia in children aged 0-59 months. J Trop Pediatr. 2010 Aug;56(4):227-34. Epub 2009 Nov 23.
- Frier BM; How hypoglycaemia can affect the life of a person with diabetes. Diabetes Metab Res Rev. 2008 Feb;24(2):87-92.
- Smeeks FC; Emergent Management of Acute Symptoms of Hypoglycemia, Medscape, Jun 2011
- Pearson T; Glucagon as a treatment of severe hypoglycemia: safe and efficacious but underutilized. Diabetes Educ. 2008 Jan-Feb;34(1):128-34.
- Cranmer H; Neonatal Hypoglycemia, Medscape, Sep 2011
|Original Author: Dr Hayley Willacy||Current Version: Dr Gurvinder Rull||Peer Reviewer: Dr Adrian Bonsall|
|Last Checked: 19/08/2011||Document ID: 461 Version: 3||© EMIS|
Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. EMIS has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions.